EMA Authorised: Elaprase (idursulfase) — Takeda Pharmaceuticals International AG Ireland Branch

View source ↗

Summary

Elaprase (idursulfase) has been authorised for worldwide or regional use in the EU for mucopolysaccharidosis II (Hunter syndrome).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Ii

Drugs mentioned

• Elaprase (idursulfase)

Snippet

Status: Authorised. Therapeutic area: Mucopolysaccharidosis II. MAH: Takeda Pharmaceuticals International AG Ireland Branch. Decision date: 04/09/2025